The International Society of Dermatology (ISD) stands at the forefront of advancing global skin health through education, collaboration and outreach.1 Established with a mission to bridge disparities in dermatological care worldwide, the ISD has become a vital hub for connecting the dermatology community, encouraging scientific exchange and promoting equitable access to dermatologic knowledge and services. […]

Pyoderma gangrenosum (PG) is a rare, painful and complex autoimmune skin condition that can present significant diagnostic and treatment challenges.1   To provide expert insights into this challenging disease, we spoke with Dr Benjamin Kaffenberger, a dermatologist at The Ohio State University (Columbus, OH, USA) specializing in the management of complex medical dermatologic conditions. Q. […]

Renowned for his work in urticaria, drug allergies and angioedema, Professor Luis FC Ensina is a distinguished allergologist. As a Professor of the Division of Allergy, Clinical Immunology and Rheumatology at the Federal University of São Paulo, Brazil and coordinator of its urticaria, angioedema, drug allergy and mast cell diseases outpatient clinic, he has made […]

touchDERMATOLOGY coverage from EADV 2024: Twice-daily continuous application of ruxolitinib cream, a topical selective JAK1/JAK2 inhibitor, has been reported to be safe and effective in treating children with mild to moderate atopic dermatitis (AD) over an 8-week period in the TRuE-AD studies.1,2 In this interview, we talk with Dr Amy Paller from the Northwestern University […]

Dr. Shari Lipner is a leading expert in dermatology, best known for her specialization in nail disorders. As an Associate Professor of Clinical Dermatology and Director of the Nail Division at New York-Presbyterian/Weill Cornell Medical Center, her work bridges both clinical care and research. With over 400 peer-reviewed publications, Dr. Lipner has significantly advanced the […]

Janus kinase inhibitors (JAKis) have transformed the landscape of dermatological therapy over the last 2 years, with six United States Food and Drug Administration approvals and further clinical trials in progress.1 JAKis have proven highly efficacious in dermatological diseases, by blocking the JAK-signal transducer and activator of transcription (STAT) signalling pathway involved in numerous inflammatory […]

Chronic spontaneous urticaria (CSU), a common and distressing skin condition driven by mast cells, is typically managed with a stepwise approach using second-generation H1-antihistamines, omalizumab and cyclosporine, as recommended by international guidelines. However, many patients with CSU do not respond optimally to this standardized treatment, likely due to the diverse underlying mechanisms involved. As a […]

The pathogenesis of cutaneous granulomatous disorders is incompletely understood and many unmet needs remain in the treatment paradigm.1 These disorders can be categorized into two main groups: those caused by infections and those associated with inflammatory skin conditions, among the most prevalent inflammatory disorders are granuloma annulare (GA) and cutaneous sarcoidosis (CS).1 The presentation of […]